Palliative resection of advanced primary hepatocellular carcinoma / 中国普通外科杂志

Objective　To evaluate the effect of palliative resection of advanced primary hepatocellular carcinoma (PHCC). Methods　98 patients with advanced PHCC were divided randomly into two groups in our hospital from March 1996 to Jan. 2000:(1) Therapy group (49 cases), dealt with palliative resection of liver cancer and implanted with a drug delivery system (DDS). (2) Control group (49 cases), only implanted with DDS. Results　In therapy group and control group, The decline rate of AFP was 60.0% and 31.7% respectively (P<0.05); and the survival rates of 0.5, 1, 3 　years after operation were 85.7% 　(42/49), 60.5%(23/38), 45.4%(10/22) and 　67.3%(33/49), 32.5%(13/40), 　10%(2/20) (P<0.05). Conclusions　Palliative resection of liver cancer can improve survival duration and life quality of patients with advanced HCC.

Combined superselective transcatheter arterial chemoembolization and selective intraportal venous embolization for the treatment of inoperable advanced primary liver cancer / 中国普通外科杂志

Objective To evaluate superselective transcatheter arterial chemoembolization ( TACE) plus selective portal vein embolization (SPVE) and large dose of lipiodol on advanced primary liver carcinoma (PHC).Methods Two hundred and three cases of advanced PHC were randomly divided into group treated with ordinary TACE, and that with TACE +SPVE. Results The response rate (CR+PR) was 38% in TACE group and 59% in TACE+SPVE group (P